NVCRHealthcare · Medical DevicesThe 7 Wall Street analysts covering NovoCure Ltd. hold a median 12-month price target of $20 — +36.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 3 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores NovoCure Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (96): Analysts have, on balance, been raising their forecasts.
Volatility (27): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on NVCR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +36.9% from it.
Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Oct 2026 | Evercore ISI Group | Maintains | Outperform | $23 → $20 |
| 30 Oct 2026 | Wells Fargo | Maintains | Equal-Weight | $20 → $15 |
| 24 July 2026 | Wedbush | Maintains | Neutral | — |
| 24 July 2026 | Wedbush | Maintains | Neutral | $18 → $20 |
| 23 July 2026 | HC Wainwright & Co. | Maintains | Buy | $46 → $52 |
| 23 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 July 2026 | JP Morgan | Reinstates | Neutral | $17 |
| 18 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 1 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 16 Apr 2026 | Wedbush | Reiterates | Neutral | — |
| 26 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Jan 2026 | Wedbush | Reiterates | Neutral | — |
| 13 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Oct 2025 | JP Morgan | Maintains | Neutral | — |
| 25 July 2025 | Wells Fargo | Downgrade | Equal-Weight | — |
| 8 July 2025 | Ladenburg Thalmann | Initiates | Buy | — |
| 27 June 2025 | Piper Sandler | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NVCR appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, NovoCure Ltd. returned +21.8% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 94% of US stocks
Cheaper than 49% of US stocks
Cheaper than 22% of US stocks
Cheaper than 87% of US stocks
Higher than 64% of US stocks
Higher than 55% of US stocks
Higher than 89% of US stocks
Higher than 30% of US stocks
Higher than 16% of US stocks
Higher than 26% of US stocks
Higher than 30% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
NovoCure Ltd. has a market value of $1.5B and an enterprise value of $1.3B.
Revenue in the twelve months to 30 June 2026: $699.2M. The latest quarter grew 15.7% year on year.
Net income over the same four quarters: −$148.6M, a −21.2% net margin.
Diluted earnings per share, trailing twelve months: $−1.30.
Free cash flow in the twelve months to 30 June 2026: −$25.4M, after $22.6M of capital spending.
Trailing P/E: −11.0×; forward P/E: −18.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
NovoCure Ltd. employs 1,605 people — $436K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own NovoCure Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights changes in NovoCure’s international revenue and discusses their impact on Wall Street predictions and the stock’s prospects.
Why it matters — International revenue trends may inform how NVCR watchers assess analyst expectations and the company’s outlook.
NovoCure reported record third-quarter net revenue of $193 million. Active glioblastoma patients increased 11% year over year to 4,730.
Why it matters — The revenue and patient growth figures provide NVCR watchers with an update on the company’s business performance.
NovoCure held its Q3 2026 earnings call on October 29, 2026. The excerpt identifies company executives and participating analysts but provides no discussion of results or business developments.
Why it matters — The excerpt confirms the call took place, but contains no earnings details for NVCR watchers to assess.
NovoCure reported third-quarter 2026 net revenue of $193 million, up 16% year over year, with Optune Gio growth and the Japan launch of Optune Lua helping active patient counts reach a record. The company raised its full-year revenue and adjusted EBITDA outlook while noting commercial headwinds for Optune Pax in the United States.
Why it matters — NVCR watchers may note the revenue growth and higher outlook alongside the stated commercial challenges for Optune Pax.
NovoCure reported a third-quarter loss of $0.09 per share, compared with the Zacks consensus estimate of a $0.21 loss and a $0.33 loss per share a year earlier. The headline says the company also topped revenue estimates.
Why it matters — NVCR watchers may note the reported per-share loss was smaller than the consensus estimate and the year-ago loss.
The 7 Wall Street analysts covering NovoCure Ltd. have a median 12-month price target of $20, with estimates ranging from $15 to $52. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering NovoCure Ltd., 4 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NovoCure Ltd. 97 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, NovoCure Ltd. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (96 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +36.9% from the last close, and Ticker Nerd's factor model ranks NovoCure Ltd. 97 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering NovoCure Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NVCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $52 over the next 12 months.
NovoCure Ltd. returned +21.8% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
NovoCure Ltd. is a global oncology company focused on developing and commercializing Tumor Treating Fields, a non-invasive cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cell division.
The most recent item we track (Zacks Investment Research, 2 Nov 2026): "Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock". Zacks Investment Research highlights changes in NovoCure’s international revenue and discusses their impact on Wall Street predictions and the stock’s prospects.
NovoCure Ltd. is a global oncology company focused on developing and commercializing Tumor Treating Fields, a non-invasive cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cell division. Its current commercial portfolio includes Optune Gio for glioblastoma and Optune Lua for malignant pleural mesothelioma, with these therapies used alongside standard cancer treatments in approved markets. The company operates across the United States, Europe, Japan, Greater China, and other international regions, supporting patients through portable device-based treatment systems and related services. NovoCure Ltd. plays a specialized role in the cancer care market by offering a device-led treatment platform for difficult-to-treat solid tumors, combining medical technology, clinical support, and oncology-focused commercialization.
CEO Mr. Frank Leonard · 1,605 employees · Switzerland · https://www.novocure.com
